Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 10/20 | 0.49 |
| ▸ | PPARA | Q07869 | 10/20 | 0.49 |
| ▸ | PPARD | Q03181 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934565 | 0.89 | PPARG (0.44) | PPARGPPARAPPARDMAPT | |
| SCHEMBL1934897 | 0.88 | NPC1 (0.56) | L3MBTL1PPARGPPARAPPARDLMNA | |
| SCHEMBL1935387 | 0.86 | PPARD (0.46) | PPARGPPARAPPARD | |
| SCHEMBL1935430 | 0.84 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL1934554 | 0.83 | PPARA (0.58) | PPARGPPARAPPARDCYP1A2 | |
| SCHEMBL12083180 | 0.83 | THRA (0.51) | PPARGPPARAALDH1A1MAPTTHRB | |
| SCHEMBL1935010 | 0.81 | PPARD (0.57) | PPARGPPARAPPARD | |
| SCHEMBL1934701 | 0.81 | PPARA (0.59) | PPARGPPARAPPARDCYP1A2 | |
| SCHEMBL2029604 | 0.81 | PPARD (0.48) | PPARGPPARAPPARDALDH1A1 | |
| SCHEMBL1934856 | 0.78 | PPARA (0.49) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046715-B1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2014-04-16 | — | — | EP | claimed |
| US-8258182-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-09-04 | — | — | US | claimed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | claimed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-07-17 | — | — | US | disclosed |
| EP-2641596-B1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-05-02 | — | — | EP | disclosed |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-12-28 | — | — | US | disclosed |
| US-8258182-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258182-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-09-04 | — | — | US | disclosed |
| WO-2011080276-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DPP-4 INHIBITOR AND A 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE | GENFIT (FR) | 2011-07-07 | — | — | WO | disclosed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | disclosed |
| WO-2011064350-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2011-06-03 | — | — | WO | disclosed |
| WO-2007147879-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP4, CYP3A43 | L3MBTL1 3028/4885PPARG 84/4885PPARA 16/4885 |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | L3MBTL1 2532/4885PPARG 119/4885PPARA 65/4885 |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP8, DPP4 | L3MBTL1 3321/4885PPARG 56/4885PPARA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.